The First Akkermansia Muciniphila Ingredient Approved for Muscle Health: BiomeNrich™ POST M005
Pioneering Muscle Health with BiomeNrich™ POST M005
CJ BIO’s BiomeNrich™ POST M005 has made waves in the health and nutrition industry by becoming the first ingredient derived from Akkermansia muciniphila to receive New Dietary Ingredient Notification (NDIN) approval from the U.S. FDA. This landmark recognition not only vouches for the ingredient's safety but also expands its potential applications in dietary and functional foods.
Understanding Akkermansia Muciniphila
Akkermansia muciniphila is a well-documented microbe known primarily for its beneficial effects on gut health and metabolic processes. Researchers have pointed to its capabilities in weight management, inflammation reduction, and prevention against various metabolic diseases. Despite its recognized benefits, the intricate regulatory landscape has typically limited its commercial leverages. With the FDA's formal acknowledgment, BiomeNrich™ POST M005 is now poised to overcome such barriers, enabling more brands to harness its advantages.
Features of BiomeNrich™ POST M005
BiomeNrich™ POST M005 is classified as a postbiotic ingredient, produced through a unique pasteurization process that effectively inactivates microbes. This method enhances the ingredient’s stability, safety, and efficacy, putting it ahead of traditional probiotics often found in the market.
The efficacy of BiomeNrich™ POST M005 in supporting muscle health was assessed in a comprehensive, double-blind, placebo-controlled clinical trial involving 92 participants over a 12-week period. The results were impressive:
- - Participants experienced a 200% increase in leg strength compared to those on the placebo.
- - There was a notable increase in follistatin levels, a key muscle-supporting protein, by 130%.
This trial substantiates the ingredient's claim as a viable option for promoting muscle health, leading to its strong positioning in the market.
CJ BIO’s Commitment to Innovation
CJ BIO's dedication to enhancing the nutrition sector is underscored by its exclusive global license to market BiomeNrich™ POST M005. A representative from the company expressed enthusiasm about the approval, stating, "We are pleased to contribute to the growth of the nutrition industry, particularly concerning muscle health and healthy aging. With the approval of NDI, we anticipate a surge in CPG brands crafting unique offerings in the market with BiomeNrich™ POST M005.
This innovative step not only reinforces CJ BIO's leadership in functional ingredients but also sets a precedent for future ingredient development in the nutritional domain.
About CJ BIO
CJ BIO is a key business unit within CJ CheilJedang, a subsidiary of the CJ Group operating since 1953 in South Korea. CJ Group specializes in diverse areas including Food, Bio Pharma, Media, and Logistics. As a leader in fermentation-based bio-products, CJ BIO supplies a comprehensive range of offerings, such as TasteNrich®, FlavorNrich™, AMINATURE®, and BiomeNrich™
Once again, CJ BIO is advancing the frontier of functional ingredients, merging scientific research with innovative practices to cater to evolving consumer health and nutrition needs. As the dietary supplement market continues to expand, ingredients like BiomeNrich™ POST M005 are likely to become increasingly valuable assets in formulating future-forward products.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.